Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Kanāda - angļu - Health Canada

pro doc limitee - sucralfate - tablet - 1g - sucralfate 1g - protectants

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

atlantic biologicals corp. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

pacific pharma, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

pacific pharmaceuticals limited (part of mylan) - sucralfate 0.5 g - chewable tablet - 0.5 g - active: sucralfate 0.5 g

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

pacific pharmaceuticals limited (part of mylan) - sucralfate - tablet - 0.5g, 1.0g - active: sucralfate

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

pacific pharmaceuticals limited (part of mylan) - sucralfate 1 g - powder for oral solution - 1 g - active: sucralfate 1 g

Kanāda - angļu - Health Canada

teva canada limited - sucralfate - tablet - 1g - sucralfate 1g - protectants

Kanāda - angļu - Health Canada

apotex inc - sucralfate - tablet - 1g - sucralfate 1g - protectants

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

allergan, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - carafate (sucralfate) oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. carafate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.